文献速递糖尿病肥胖与代谢综合征

2型糖尿病非胰岛素药物治疗对血糖、心肾及体重的影响

Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本小型综述检索PubMed数据库,纳入近期系统综述、Meta分析及原始研究,评估2型糖尿病非胰岛素非注射药物治疗对血糖控制及心肾结局的影响。结果显示,钠-葡萄糖共转运蛋白2抑制剂改善心血管死亡和透析时间,肠促胰素类疗法改善心血管和肾脏复合结局,具有心肾获益的药物应根据患者风险优先使用。尽管有新药和治疗指南,多数糖尿病患者血糖仍高于目标值,作者鼓励临床医生遵循指南。

要点

  • 钠-葡萄糖共转运蛋白2抑制剂改善糖尿病患者心血管死亡和透析时间。
  • 肠促胰素类疗法改善合并心血管疾病患者的心血管和肾脏复合结局。
  • 具有心肾获益证据的药物应根据患者风险优先使用。

核心结论

  • 具有心血管和肾脏获益证据的药物应根据患者风险优先使用。
  • 尽管新药和技术、指南及治疗算法可用,多数糖尿病患者血糖仍高于目标值,作者鼓励临床医生遵循指南使用适当药物。

研究设计与样本

  • 本小型综述检索PubMed数据库,纳入人群水平数据、近期系统综述、Meta分析及原始研究文章。

主要发现

  • 钠-葡萄糖共转运蛋白2抑制剂改善糖尿病患者心血管死亡和透析时间。
  • 肠促胰素类疗法改善合并心血管疾病的糖尿病患者的心血管和肾脏复合结局。
  • 所有非胰岛素药物通过不同机制最终不同程度改善血糖,但仅部分药物显示改善重要临床心血管和肾脏结局。

关键数值与推荐

  • 原文未报告具体数值标准。

临床怎么用

  • 作者鼓励临床医生遵循指南,使用适当药物以降低心血管风险、延缓慢性肾脏病进展、达到血糖目标并管理体重。
  • 作者认为具有心血管和肾脏获益证据的药物应根据患者风险优先使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The incidence of diabetes is growing at an alarming rate globally. Most of these projected individuals will develop type 2 diabetes (T2DM), raising their risk of cardiovascular disease and chronic kidney disease. This mini-review examines current noninsulin and noninjectable pharmacotherapy focused in T2DM, highlighting the effect on glycemic control and importance of cardiovascular and renal outcomes. EVIDENCE ACQUISITION: We included population level data and searched the PubMed database for recent systematic reviews, meta-analyses, and original research articles. EVIDENCE SYNTHESIS: There is a pharmacologic menu of noninsulin-based medications for the treatment of diabetes. Through varying mechanisms, all agents ultimately lead to glycemic improvement to varying degrees. Only a select number of agents are shown to improve important clinical cardiovascular and renal outcomes. Of note, sodium-glucose cotransporter-2 inhibitors have improved cardiovascular mortality and time to dialysis in people with diabetes. Likewise, incretin-based therapies have improved important cardiovascular and renal composite outcomes in those with diabetes and cardiovascular disease. As a result, agents with proven cardiovascular and renal benefits should be prioritized based on patient risk. CONCLUSION: Despite the availability of new medications and technology, published clinical guidelines, and treatment algorithms, most people with diabetes remain above glycemic targets. We encourage clinicians to follow the guidelines and use appropriate medications to lower cardiovascular risk, delay progression of chronic kidney disease, reach glycemic targets, and manage weight.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Fetzner J, Rafi E. Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 39998927. doi:10.1210/clinem/dgae817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。